Description of potential effects of the substance based on literature. (This is not a product description, disclaimer at the bottom of the page)
Thymosin β4 (Tβ4), also known as timbetasin, is a small protein produced naturally in the body. It is made up of 43 amino acids and is now gaining popularity as a powerful, versatile therapeutic agent. In the heart, Tβ4 supports healing processes in several important ways: it activates repair programmes early in life (development), helps the cells lining the heart and blood vessels to become more elastic, reduces harmful oxidative stress and inflammation, and prevents scar tissue accumulation (fibrosis).
Early studies in both embryos and adult animals have shown that administration of Tβ4 can 'awaken' repair signals that are normally only active during development. This leads to a thickening of the heart lining (ulceration), an increase in the number of healing cells, better growth of blood vessels and improved survival of myocardial cells, even without myocardial infarction. Tβ4 has been tested as a therapeutic agent in several laboratory (pre-clinical) and animal studies. Whether administered intravenously or as a slow-release patch, Tβ4 improves cardiac function and increases the number of small blood vessels after myocardial infarction.
Thymosin β4 helps the heart to heal by reactivating embryonic programmes. Studies in mouse embryos have shown that it is naturally active during early heart development, where it helps heart cells to grow and survive [1]. In adult mice with blocked coronary arteries (a model of myocardial infarction), intravenous administration of thymosin β4 improved cardiac function, helped heart cells survive and increased the growth of new blood vessels. Interestingly, even in the healthy hearts of adult individuals without injury, thymosin β4 injections induced structural and molecular changes in the outer layer of the heart (the amniotic membrane) that resembled changes observed during development. These included the activation of some stem cell-like cells and the incorporation of genes that normally only occur during heart formation. These effects occurred without oxygen deprivation, meaning that thymosin β4 alone can activate the body's natural repair systems. Based on these results, thymosin β4 appears promising for treating age-related tissue damage and regenerating heart tissue.
Thymosin β4 promotes repair of the heart and blood vessels after damage. Shrivastava et al. (2010) highlighted the ability of thymosin β4 to protect cardiac cells after injury, promote the growth of new blood vessels and stimulate the heart's own stem cells [2]. Even without injury, it caused a thickening of the epicardium and increased the population of cardiac progenitor cells and blood vessels. This means that its therapeutic effect is not just a response to injury. It is the first molecule that has been shown to activate myocardial and vascular repair when injected into the bloodstream, making it a promising agent for the treatment of heart disease caused by low oxygen levels.
In order for thymosin β4 to work better at sites of cardiac damage, Huang et al. (2017) created nanoparticles labelled with a small peptide called CREKA, which binds to blood clots in damaged heart tissue [3]. These modified molecules (CNP-Tβ4) carried thymosin β4 directly to the damaged areas. In laboratory tests, they bound to fibrin clots much better than the untargeted versions. In live mice with cardiac damage, targeted thymosin β4 reached the damaged tissue more efficiently, stayed there longer and helped repair the heart better than the non-targeted forms. These results show that targeting thymosin β4 specifically to sites of damage can improve its therapeutic properties.
In another study, Spurney et al. (2010) tested thymosin β4 in a mouse model of Duchenne muscular dystrophy (called mouse mdx) to see if it could help muscle regeneration and improve strength [4]. Female mice mdx and healthy control mice received thymosin β4 injections (150 μg, twice a week) for six months, while being subjected to exercise to worsen symptoms. Thymosin β4 was detected in regenerating muscle fibres and increased the number of new muscle cells, showing that it helped the tissues to repair themselves. However, these benefits did not translate into muscle strengthening or improved cardiac function, and scarring was not reduced. Thus, although it improved the appearance of tissues under the microscope, it did not lead to functional improvement in this long-term experiment at the dose and schedule used.
Thymosin β4 enhances the effect of stem cell therapy after myocardial infarction. Ye et al (2013) investigated whether thymosin β4 in an extended-release form could enhance the efficacy of porcine mesenchymal stem cells (sMSCs) when both substances were administered via fibrin patch in rats after myocardial infarction (myocardial infarction) [5]. In laboratory experiments under low-oxygen conditions, the addition of 1 µg/ml thymosin β4 protected cells by reducing cell death markers such as lactate dehydrogenase leakage, TUNEL-positive cells and caspase-8 activity. It also increased the levels of Bcl-xL, a protein that helps cells to survive. In live animals, the group receiving both sMSCs and thymosin β4 had significantly better cardiac function after 4 weeks, with a left ventricular ejection fraction (LVEF) of 51.7% and fractional shortening of 26.7%. The damaged heart wall was also significantly thicker, twice as thick as in untreated animals. This helped the stem cells to survive and stay in the heart longer, promoted the growth of new blood vessels and attracted natural cardiac stem cells (c-Kit⁺ ) to the damaged area [5].
Interestingly, thymosin β4 restarts the cardiac repair programmes observed during development. Smart et al. (2007) found that thymosin β4 plays an important role during embryonic cardiac development, particularly in the construction of cardiac blood vessels [6]. This is done by promoting the migration of epicardial-derived cells (EPDCs) and their transformation into smooth muscle and endothelial cells. In adult hearts, the myocardium secretes thymosin β4, which then reactivates the inactive epicardium. This causes the movement and transformation of epicardin-labelled cells into other supporting cells, including fibroblasts and vascular cells ( ). These effects have been observed both in tissue cultures and in live animals. It works by altering the internal structure of the cell, restoring the ability of EPDCs to change and migrate. This supports cardiac cell survival, new blood vessel growth and overall myocardial repair after injury [6].
In addition, thymosin β4 protects cardiac fibroblasts from oxidative damage. In a study using cardiac fibroblasts from newborn rats exposed to hydrogen peroxide (a source of oxidative stress), Kumar and Gupta (2011) showed that it reduced the amount of harmful reactive oxygen species (ROS) inside the cells [7]. It also increased the levels of protective enzymes such as Cu/Zn-superoxide dismutase (SOD) and catalase, decreased the Bax/Bcl-2 ratio (indicating reduced cell death) and decreased the expression of fibrosis-related genes (CTGF, collagen I and III). When these enzymes were deliberately silenced with siRNA, the cells became more susceptible to death, but thymosin β4 continued to protect them. This shows that thymosin β4 has multiple ways of protecting cardiac fibroblasts from oxidative stress and stopping harmful fibrosis processes.
Thymosin β4 protects cardiac muscle cells from oxidative stress. Wei et al (2012) studied myocardial cells from newborn rats and found that it decreased ROS levels and increased both mRNA and protein expression of Cu/Zn-SOD and catalase [8]. It also increased levels of survival proteins such as Bcl-2, while decreasing the Bax/Bcl-2 ratio that promotes cell death. At the same time, it increased the activity of anti-inflammatory genes. Even when the protective enzymes Cu/Zn-SOD and catalase were blocked, thymosin β4 still prevented cell death, demonstrating that it uses multiple overlapping strategies to protect cardiac cells from damage.
In addition, thymosin β4 promotes cardiac healing and prevents scarring in multiple ways. Gupta et al (2012) found that it improves heart health by acting simultaneously on several biological pathways [9]. In both laboratory studies and in live models of cardiac injury, it helped restore cardiac function, reduce inflammation and reduce scarring (fibrosis). One of the key pathways it activated is PI3K/Akt, known to promote cell survival and tissue repair. Thymosin β4 also supported a protein complex called ILK-Pinch-Parvin, which helps cells maintain structural stability, and blocked NF-κB, a molecule that causes inflammation, as well as genes responsible for excessive collagen production, a major cause of cardiac scarring. In cardiac support cells, called fibroblasts, it reduced harmful molecules called reactive oxygen species (ROS), enhanced natural antioxidant enzymes such as Cu/Zn-superoxide dismutase (SOD) and catalase, and promoted the expression of genes that help cells survive. At the same time, it inhibited genes responsible for tissue stiffness and fibrosis.
Thymosin β4 reduces scarring and improves blood vessel growth. Cavasin (2006) reviewed laboratory and animal studies showing that it helps heart muscle cells survive and move, while its active fragment, Ac-SDKP, reduces cardiac scarring (fibrosis) in rats with high blood pressure and reduces inflammation and scarring after myocardial infarctions in other models [10]. Ac-SDKP also helped form new blood vessels and reduced the risk of heart wall rupture after myocardial infarction in mice. Together, these benefits, such as less inflammation, reduced scarring, better blood flow and stronger myocardium, suggest that these compounds may prevent long-term damage after myocardial infarction. However, the review notes that human studies are still needed.
Research has shown fewer cardiac ruptures and better heart function after thymosin β4 treatment. In mice that had undergone a heart attack, Peng et al. (2014) administered thymosin β4 using a small pump placed under the skin [11]. The treatment lasted one to five weeks. It reduced the number of myocardial ruptures, reduced inflammation, reduced the number of dying heart cells and improved cardiac structure. After five weeks, it also increased the growth of small blood vessels and led to improved cardiac pumping power. These results show that thymosin β4 can both reduce damage and promote healing after myocardial infarction. Additionally, thymosin β4 activates the growth of blood vessels from the epicardium. Smart et al (2010) focused on how it acts on the outer layer of the heart, called the epicardium [12]. Normally, the heart has a limited capacity to form new blood vessels after injury. However, with thymosin β4, the epicardium produced more blood vessels that connected well with the cardiac circulation, especially after myocardial infarction. This happened because the epicardial cells were reprogrammed by thymosin β4 to become vessel-forming cells. These results show that it can activate the heart's own repair system by stimulating epicardial cells.
Furthermore, in a large-scale review, Hinkel et al (2018) showed that it improves vascular growth and heart function in animals with heart disease, including mice and pigs [13]. In pigs with diabetes or high cholesterol, thymosin β4 gene therapy also improved cardiac blood flow and function. It acted by promoting the survival and function of cardiac cells and blood vessels, reducing inflammation and promoting regeneration. The review confirmed that thymosin β4 gene therapy is a promising long-term treatment for heart disease. Thymosin β4 helps the heart to heal by controlling inflammation and reducing scarring after a heart attack. Researchers have found that an oxidised form of thymosin β4, called Tβ4-sulfoxide (Tβ4-SO), helps the heart and other tissues to heal by controlling inflammation and minimising scarring [14]. This has been tested on the damaged fins and hearts of zebrafish, mouse models of heart injury and cultured human immune cells in the laboratory. In zebrafish, Tβ4-SO acted after hydrogen peroxide (H₂O₂) signals induced by injury to help remove immune cells (macrophages) from the wound. The removal of macrophages accelerated healing. In mice with cardiac injury, this reduced the number of macrophages in the heart, promoted better tissue healing and resulted in smaller scars, suggesting less long-term inflammation that usually leads to fibrosis. In laboratory tests with human T cells and monocytes, Tβ4-SO reduced inflammatory signals such as interferon gamma (IFN-γ), dispersed immune cells and induced their programmed death - presumably through superoxide signalling.
Another study showed that the addition of additional thymosin β4 via gene therapy (AAV-Tβ4) helps protect the heart after myocardial infarction (myocardial infarction or MI). In this experiment, mice had a myocardial infarction caused by blockage of a coronary artery and then received an injection of thymosin β4 administered via a viral vector (AAV). In addition, laboratory studies were performed on myocardial cells (cardiomyocytes) exposed to oxidative stress and scar-producing cells (myofibroblasts) exposed to TGF-β1. After myocardial infarction, the mice had a natural increase in thymosin β4 levels, but administration of more thymosin β4 via AAV-Tβ4 improved cardiac function, reduced oxidative damage and attenuated inflammation, including decreased inflammasome activity. It also reduced the amount of collagen and fibrosis observed in heart tissue. In heart cells, it helped restore a protective process called mitophagy, which keeps mitochondria healthy and is essential for strong heart contractions. In scar-forming cells, it slowed their growth and blocked their activation by TGF-β1, a key driver of fibrosis.
Conclusion: why is thymosin β4 important for cardiac healing?
Thymosin β4 is a small molecule with a big effect. It protects heart cells, helps form new blood vessels and prevents scarring. Most importantly, it activates powerful repair programmes in the early adult heart. This makes it a potential option not only for treatment after heart attacks, but also for maintaining heart health as we age. In many models of heart damage, it restores elasticity to the heart lining and blood vessels, protects muscles and supporting cells from stress and reduces scarring that weakens the heart. These effects help thicken the damaged heart wall, improve heart function and reduce the risk of serious problems such as wall rupture after a heart attack. Particularly exciting is the fact that it can turn on early repair signals in the adult heart. The next challenge is to convert this powerful biological potential into real, sustainable results through well-designed clinical trials. However, researchers need to better align structural repair processes with actual improvements in heart function in various diseases. The inconclusive results in muscular dystrophy remind us that time, dose and type of cardiac damage matter.
Disclaimer
This article has been written for educational purposes and is intended to raise awareness of the substance under discussion. It is important to note that the article is about the substance in general - it is not a description of a specific product (chemical reagent). We are not suggesting the use of chemical reagents on humans - this is prohibited by law, for a product to be used for treatment it must be registered as a medicine. The information contained in the text is based on available scientific research and is not intended as medical advice or to promote self-medication. The reader should consult with a qualified health professional for all health and treatment decisions.
References
- Bock-Marquette, I., Maar, K., Maar, S., Lippai, B., Faskerti, G., Gallyas, F. Jr., Olson, E. N. and Srivastava, D. (2023). Thymosin beta-4 sets new directions for the development of effective anti-aging regenerative therapies. International Immunopharmacology, 116, 109741. https://doi.org/10.1016/j.intimp.2023.109741 https://pubmed.ncbi.nlm.nih.gov/36709593/
- Shrivastava, S., Srivastava, D., Olson, E. N., DiMaio, J. M. and Bock-Marquette, I. (2010). Thymosin beta4 and cardiac regeneration. Annals of the New York Academy of Sciences, 1194, 87-96. https://doi.org/10.1111/j.1749-6632.2010.05468.xhttps://pubmed.ncbi.nlm.nih.gov/20536454/
- Huang, Z., Song, Y., Pang, Z., Zhang, B., Yang, H., Shi, H., Chen, J., Gong, H., Qian, J. and Ge, J. (2017). Targeted delivery of thymosin beta 4 to injured myocardium using CREKA-conjugated nanoparticles. International Journal of Nanomedicine, 12, 3023-3036. https://doi.org/10.2147/IJN.S131949 https://pubmed.ncbi.nlm.nih.gov/28442910/
- Spurney, C. F., Cha, H. J., Sali, A., Pandey, G. S., Pistilli, E., Guerron, A. D., Gordish-Dressman, H., Hoffman, E. P. and Nagaraju, K. (2010). Assessment of skeletal and cardiac muscle function following long-term administration of thymosin beta-4 to dystrophin-deficient mice. PLoS ONE, 5(1), e8976. https://doi.org/10.1371/journal.pone.0008976https://pubmed.ncbi.nlm.nih.gov/20126456/
- Ye, L., Zhang, P., Duval, S., Su, L., Xiong, Q. and Zhang, J. (2013). Thymosin β4 enhances the efficacy of transplanted mesenchymal stem cells in myocardial repair. Circulation, 128(11 Suppl 1), S32-S41. https://doi.org/10.1161/CIRCULATIONAHA.112.000025https://pubmed.ncbi.nlm.nih.gov/24030419/
- Smart, N., Risebro, C. A., Melville, A. A. D., Moses, K., Schwartz, R. J., Chien, K. R. and Riley, P. R. (2007). Thymosin beta-4 is essential for coronary vascular development and promotes neovascularisation through the adult epicardium. Annals of the New York Academy of Sciences, 1112, 171-188. https://doi.org/10.1196/annals.1415.000 https://pubmed.ncbi.nlm.nih.gov/17495252/
- Kumar, S., & Gupta, S. (2011). Thymosin beta 4 prevents oxidative stress by acting on antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS ONE, 6(10), e26912. https://doi.org/10.1371/journal.pone.0026912 https://pubmed.ncbi.nlm.nih.gov/22046407/
- Wei, C., Kumar, S., Kim, I.-K. and Gupta, S. (2012). Thymosin beta 4 protects cardiomyocytes from oxidative stress by acting on antioxidant enzymes and anti-apoptotic genes. PLoS ONE, 7(8), e42586. https://doi.org/10.1371/journal.pone.0042586 https://pubmed.ncbi.nlm.nih.gov/22880044/
- Gupta, S., Kumar, S., Sopko, N., Qin, Y., Wei, C. and Kim, I.-K. (2012). Thymosin β4 and cardiac protection: effects on inflammation and fibrosis. Annals of the New York Academy of Sciences, 1269, 84–91. https://doi.org/10.1111/j.1749-6632.2012.06752.x https://pubmed.ncbi.nlm.nih.gov/23045975/
- Cavasin, M. A. (2006). Therapeutic potential of thymosin beta4 and its N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) derivative in the treatment of the heart after myocardial infarction. American Journal of Cardiovascular Drugs, 6(5), 305–311. https://doi.org/10.2165/00129784-200606050-00003 https://pubmed.ncbi.nlm.nih.gov/17083265/
- Peng, H., Xu, J., Yang, X.-P., Dai, X., Peterson, E. L., Carretero, O. A., & Rhaleb, N.-E. (2014). Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology, 307(5), H741-H751. https://doi.org/10.1152/ajpheart.00129.2014 https://pubmed.ncbi.nlm.nih.gov/25015963/
- Smart, N., Risebro, C. A., Clark, J. E., Ehler, E., Miquerol, L., Rossdeutsch, A., Marber, M. S. and Riley, P. R. (2010). Thymosin beta4 facilitates epicardial neovascularization in the injured adult heart. Annals of the New York Academy of Sciences, 1194, 97-104. https://doi.org/10.1111/j.1749-6632.2010.05478.x https://pubmed.ncbi.nlm.nih.gov/20536455/
- Hinkel, R., Klett, K., Bähr, A. and Kupatt, C. (2018). Protective effects of thymosin β4 in the heart. Expert Opinion on Biological Therapy, 18(sup1), 121–129. https://doi.org/10.1080/14712598.2018.1490409 https://pubmed.ncbi.nlm.nih.gov/30063857/
- Evans, M. A., Smart, N., Dubé, K. N., Bollini, S., Clark, J. E., Evans, H. G., Taams, L. S., Richardson, R., Lévesque, M., Martin, P., Mills, K., Riegler, J., Price, A. N., Lythgoe, M. F., & Riley, P. R. (2013). Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nature Communications, 4, 2081. https://doi.org/10.1038/ncomms3081 https://pubmed.ncbi.nlm.nih.gov/23820300/
- Wang, F., He, Y., Yao, N., Ruan, L., & Tian, Z. (2022). Thymosin β4 protects against cardiac injury and subsequent cardiac fibrosis in mice with myocardial infarction. Cardiovascular Therapeutics, 2022, 1308651. https://doi.org/10.1155/2022/1308651 https://pubmed.ncbi.nlm.nih.gov/35712678/